eMedicine Specialties > Ophthalmology > Refractive Disorders

Myopia, PRK: Treatment

Author: Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES
Contributor Information and Disclosures

Updated: Apr 18, 2006

Treatment

Medical Therapy

Following PRK, topical antibiotics should be used with a therapeutic contact lens until reepithelialization is complete. Furthermore, a weak corticosteroid, such as fluorometholone 0.1%, frequently is used to avoid excessive collagen deposition.

Topical intraoperative application of 0.02% mitomycin C can reduce haze formation in highly myopic eyes undergoing PRK.

Preoperative Details

Preoperative evaluation before PRK includes the following:

  • Refractive history (including history of contact lens wear)
  • Keratometry
  • Uncorrected and best-corrected visual acuity
  • Manifest and cycloplegic refraction
  • Videokeratography and keratometry
  • Slit lamp examination
  • Tonometry
  • Dilated funduscopy
  • Assessment of a patient's ability to tolerate the procedure under topical anesthesia, to fixate steadily, to lie flat without difficulty, to understand the nature of the procedure, and to give an informed consent

Intraoperative Details

After placement of antibiotic and anesthetic drops in the eye, the eyelid is held open using a speculum. When using the mechanical epithelial removal technique, a 6.0- or 6.5-mm marker can be used, centered over the entrance pupil to mark the area where the epithelium is to be removed. The epithelium can be removed using a blunt spatula or a small blade, such as a Beaver 64.

After epithelial removal, the surface of the cornea must be wiped with a nonfragmenting sponge that has been soaked with balanced sterile saline and then squeezed so it is moist but not saturated. During the procedure, focusing properly on the stromal surface and avoiding excessive illumination to allow patient fixation are important. A Thornton ring or similar instrument can be used to gently help the patient maintain fixation without distorting the corneal surface.

The excimer laser beam is centered on the entrance pupil and focused on the anterior stromal surface, and the laser treatment is applied.

Postoperative Details

Placing a therapeutic contact lens for an average of 3 days is helpful, as well as using a combination of antibiotic/steroid drops. Alternatively, a pressure patch following application of an antibiotic/steroid ointment is well tolerated. Analgesic and antianxiety oral medications should be used during the first 24 hours postoperatively.

Follow-up

Patients should be monitored daily after PRK until the reepithelialization is complete. At this time, the therapeutic contact lens can be removed, and the patient can be monitored 1 week later. The remaining follow-up interval times can double until the vision stabilizes.

For excellent patient education resources, visit eMedicine's Eye and Vision Center. Also, see eMedicine's patient education article Vision Correction Surgery.

Complications

Complications following PRK include the following:

  • Undercorrections, overcorrections, and induced astigmatism: As the most common complications that occur following PRK, they may be caused by inadequate centration or focusing at the time of surgery. Management of these complications often includes a retreatment using either a second PRK procedure or LASIK after the initial result has stabilized
  • Regression: This complication may occur postoperatively, particularly in young patients or those with high corrections for up to 6 months following PRK. Initial treatment with topical steroids may halt regression. If a regression results in visually significant changes, a PRK or LASIK retreatment can be performed once refractive stabilization has been documented.
  • Reticular stromal haze: Why some patients develop this pattern on the anterior stroma is unclear. It has been associated with the use of postoperative nonsteroidal anti-inflammatory drugs (NSAIDs). In many cases, it does not affect a patient´s visual acuity. Initial management of corneal haze usually consists of waiting until the opacity fades spontaneously. Treatment of persistent moderate-to-severe haze includes the use of topical steroids and/or a second laser application (eg, PRK, phototherapeutic keratectomy [PTK]). Only haze that is causing a reduction in visual acuity should be considered for retreatment. An association exists between significant regression and the formation of severe reticular haze.
  • Increase in intraocular pressure (IOP) associated with the use of postoperative steroids: In all cases, IOP reverts to normal values on discontinuation of topical steroids. No reports of persistent increased IOP exist in the literature.
  • Steroid-induced herpes simplex keratitis: This complication may be associated with the use of postoperative steroids or possibly from the stress of the excimer laser. In patients with a known history of herpes simplex viral keratitis, the use of preoperative and postoperative topical/oral acyclovir or trifluorothymidine drops is warranted.
  • Posterior subcapsular cataracts: These have been reported infrequently in patients who used dexamethasone phosphate postoperatively.
  • Superficial keratopathy: This has been reported in association with topical NSAIDs or the preservatives used in other drops.
  • Complications related to the use of therapeutic contact lenses, including infectious keratitis: Treatment of this complication requires corneal scrapings for culture and sensitivity, as well as the use of fortified topical antibiotics.
  • Sterile paracentral corneal infiltrates: These infiltrates can be treated with fortified topical antibiotics and topical steroids, respectively
  • Delayed epithelial healing: This can occur in some patients, requiring a longer period of time with therapeutic contact lens to allow epithelium regeneration.
  • Recurrent corneal erosions: This complication may occur in the presence of basement dystrophy unrecognized during the preoperative evaluation. The treatment may include PTK and the use of hypertonic saline solution.
  • Decentration of the ablation zone: This may occur following inadequate centration on the entrance pupil at the time of laser application. The treatment may include a retreatment guided by corneal topography and/or 3D corneal topography (elevation map).
  • Central islands: Excimer lasers with a flattop energy beam profile have the potential of producing central islands. Four main theories exist as to the cause of central islands, as follows: focal central epithelial hyperplasia, the vortex plume theory, degradation of laser optics, and the acoustic shock wave theory. However, central island formation is most likely multifactorial. Modern excimer lasers have built-in software to neutralize the possible appearance of central islands. This software acts by centrally applying additional pulses.
  • Corneal melting and perforation: This has been reported in patients with connective tissue disease. A penetrating keratoplasty may be necessary in these cases to restore vision and ocular integrity.

More on Myopia, PRK

Overview: Myopia, PRK
Workup: Myopia, PRK
Treatment: Myopia, PRK
Follow-up: Myopia, PRK
References

References

  1. Dausch D, Smecka Z, Klein R, et al. Excimer laser photorefractive keratectomy for hyperopia. J Cataract Refract Surg. Mar 1997;23(2):169-76. [Medline].

  2. Erie JC, McLaren JW, Hodge DO. Recovery of corneal subbasal nerve density after PRK and LASIK. Am J Ophthalmol. Dec 2005;140(6):1059-1064. [Medline].

  3. Gambato C, Ghirlando A, Moretto E. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology. Feb 2005;112(2):208-18; discussion 219. [Medline].

  4. Krueger RR, Trokel SL. Quantitation of corneal ablation by ultraviolet laser light. Arch Ophthalmol. Nov 1985;103(11):1741-2. [Medline].

  5. McDonald MB, Kaufman HE, Frantz JM, et al. Excimer laser ablation in a human eye. Case report. Arch Ophthalmol. May 1989;107(5):641-2. [Medline].

  6. Munnerlyn CR, Koons SJ, Marshall J. Photorefractive keratectomy: a technique for laser refractive surgery. J Cataract Refract Surg. Jan 1988;14(1):46-52. [Medline].

  7. O'Brart DP, Patsoura E, Jaycock P. Excimer laser photorefractive keratectomy for hyperopia: 7.5-year follow-up. J Cataract Refract Surg. Jun 2005;31(6):1104-13. [Medline].

  8. Paysse EA, Coats DK, Hussein MA. Long-term outcomes of photorefractive keratectomy for anisometropic amblyopia in children. Ophthalmology. Feb 2006;113(2):169-76. [Medline].

  9. Rajan MS, Jaycock P, O'Brart D. A long-term study of photorefractive keratectomy; 12-year follow-up. Ophthalmology. Oct 2004;111(10):1813-24. [Medline].

  10. Seiler T, Wollensak J. Myopic photorefractive keratectomy with the excimer laser. One-year follow-up. Ophthalmology. Aug 1991;98(8):1156-63. [Medline].

  11. Shaikh NM, Wee CE, Kaufman SC. The safety and efficacy of photorefractive keratectomy after laser in situ keratomileusis. J Refract Surg. Jul-Aug 2005;21(4):353-8. [Medline].

  12. Taboada J, Archibald CJ. An extreme sensitivity in the corneal epithelium to far UV ArF excimer laser pulses. Proceedings of the Aerospace Medical Association. San Antonio;1981.

  13. Tanzer DJ, Isfahani A, Schallhorn SC. Photorefractive keratectomy in African Americans including those with known dermatologic keloid formation. Am J Ophthalmol. Nov 1998;126(5):625-9. [Medline].

  14. Taylor HR, Guest CS, Kelly P, Alpins NA. Comparison of excimer laser treatment of astigmatism and myopia. The Excimer Laser and Research Group. Arch Ophthalmol. Dec 1993;111(12):1621-6. [Medline].

  15. Uozato H, Guyton DL. Centering corneal surgical procedures. Am J Ophthalmol. Mar 15 1987;103(3 Pt 1):264-75. [Medline].

  16. Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. Dec 1994;35(13):4344-7. [Medline].

Further Reading

Keywords

photorefractive keratectomy, shortsighted, vision loss, visual deficit, laser surgery

Contributor Information and Disclosures

Author

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES
Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology
Disclosure: Nothing to disclose.

Medical Editor

Daniel S Durrie, MD, Director, Department of Ophthalmology, Division of Refractive Surgery, University of Kansas Medical Center
Daniel S Durrie, MD is a member of the following medical societies: American Academy of Ophthalmology and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Louis E Probst, MD, Medical Director of Refractive Surgery, Chicago, Madison, Milwaukee, and Windsor Centers, TLC the Laser Eye Centers
Louis E Probst, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, and International Society of Refractive Surgery
Disclosure: Nothing to disclose.

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.